BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 27342030)

  • 1. Biological agents and biosimilars: Essential information for the internist.
    Pasina L; Casadei G; Nobili A
    Eur J Intern Med; 2016 Sep; 33():28-35. PubMed ID: 27342030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biosimilars, the journey has begun].
    Martos-Rosa A; Martínez-de la Plata JE; Morales-Molina JA; Fayet-Pérez A; Acosta-Robles PJ
    Farm Hosp; 2015 Mar; 39(2):114-7. PubMed ID: 25817091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
    Oza B; Radhakrishna S; Pipalava P; Jose V
    J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar medical products - licensing, pharmacovigilance and interchangeability.
    Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
    Schiestl M; Zabransky M; Sörgel F
    Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.